Document:

Prepared and filed by St Ives Burrups

Exhibit 10.8h

 May 15, 2000 

 NPS Pharmaceuticals, Inc.

  420 Chipeta Way

  Salt Lake City, Utah 84108 

 RE: Amendment Agreement 

 Dear Sirs: 

      This Amendment
  Agreement (hereinafter “Amendment Agreement”) will confirm that
  the November 1, 1993 Collaborative Research and License Agreement between NPS
  Pharmaceuticals, Inc., a corporation of the state of Delaware, having a place
  of business at 420 Chipeta Way, Salt Lake City, Utah 84108, U.S.A. (herein referred
  to as “NPS”) and SmithKline Beecham Corporation, a corporation of the Commonwealth
  of Pennsylvania, having a place of business at One Franklin Plaza, Philadelphia,
  Pennsylvania 19101, U.S.A. (hereinafter referred to as “SB”) as amended (hereinafter
  collectively referred to as “Original Agreement”) shall be further amended as
  follows:

	•	Paragraph 1.20 shall be replaced in its
      entirety with the following:
	 	 
	 	“1.20     “IND”
      shall mean an Investigational New Drug Application for COMPOUND in the FIELD
      filed by or on behalf of SB with the FDA or equivalent application(s) filed
      with the appropriate regulatory authorities in the United Kingdom, France,
      Germany, Italy, Spain or Japan, provided that the purpose of such IND is
      not to conduct experimental medicine based on a toxicology package insufficient
      to support multiple dose studies.
	 	 
	•	Paragraph 5.01 shall be amended as indicated,
      additions are indicated in bold text, deletions are indicated by
      stike through and bold text:
	 	 

	 	EFFECTIVE DATE	U.S. $ 4,000,000	 	 	 
	 	 	  	 	 	 
	 	January 1, 1995	 U.S. $ 2,000,000	 	 	 
	 	 	  	 	 	 
	 	First Program Status	U.S. $ 3,000,000	 	 	 
	 	 	  	 	 	 
	 	First Experimental Medicine IND	U.S. $ 1,000,000	 	 	 
	 	 	  	 	 	 
	 	First IND	U.S. $ 2,000,000	 	(3,000,000)	 
	 	 	  	 	 	 
	 	NDA Filing for First COMPOUND	U.S. $ 5,000,000	 	 	 
	 	 	  	 	 	 
	 	Second Program Status	U.S. $ 2,000,000	 	 	 
	 	 	  	 	 	 
	 	First IND for Second COMPOUND	U.S. $ 2,000,000	 	 	 
	 	 	  	 	 	 
	 	Third Program Status	U.S. $ 1,000,000	 	 	 
	 	 	  	 	 	 
	 	First IND for Third COMPOUND	U.S. $ 1,000,000	 	 	 

Page 1

	•	Add the following as new Paragraph
      5.01(1):
	 
	     “(I)
      by the term "First Experimental Medicine IND” as used in this
      Paragraph 5.01 is meant the first Investigational New Drug Application for
      any COMPOUND in the FIELD filed by or on behalf of SB with the FDA provided
      that the purpose of such IND is to conduct experimental medicine human trials
      based on a toxicology package insufficient to support multiple dose studies.
      Multiple dose studies shall not include single doses separated by a wash-out
      period equivalent to at least 7 days or 5 half-lives of the COMPOUND.
	 
	•	This Amendment Agreement shall
      be retroactively effective as of November 1, 1993.
	 	 
	•	All other terms and conditions
      of the Original Agreement shall remain in full force and effect.

           Please
  indicate your acceptance of this Amendment
  Agreement by signing and dating the duplicate copies of this letter below and
  returning one such fully executed copy to SB. 

	 	Very truly yours,

      SMITHKLINE BEECHAM CORPORATION 
	 	 
	 	 
	 	By:	/s/ Donald F. Parman
	 	 	 Donald F. Parman
	 	Title:	Secretary
	 	Date:	May 15, 2000

 AGREED TO AND ACCEPTED:

  NPS PHARMACEUTICALS, INC. 

	By:	/s/ James K. Jensen
	  	James K. Jensen
	Title:	Vice President
	 	 
	Date:	May 15, 2000

Page 2Prepared and filed by St Ives Burrups

  Exhibit 10.8I

	           	 GlaxoSmithKline
      

      One Franklin Plaza 

      P.O. Box 7929 

      Philadelphia, PA 

      19101-7929

      

      Tel. 215 751 4000

      Fax. 215 751 3400 

      www.gsk.com

	         	August 1, 2001

NPS Pharmaceuticals, Inc. 

  420 Chipeta Way

  Salt Lake City, Utah 84108

RE: Amendment Agreement to Amend the January 24, 2000 Amendment Agreement

Dear Sirs:

This Amendment Agreement
  to amend the January 24, 2000 Amendment Agreement will confirm that the Letter
  Agreement dated November 26, 1997 between NPS Pharmaceuticals, Inc., a corporation
  of the state of Delaware, having a place of business at 420 Chipeta Way, Salt
  Lake City, Utah 84108, U.S.A. (herein referred to as “NPS”) and
  SmithKline Beecham Corporation, a GlaxoSmithKline Company, a corporation of
  the Commonwealth of Pennsylvania, having a place of business at One Franklin
  Plaza, Philadelphia, Pennsylvania 19101, U.S.A. (hereinafter referred to as
  “GSK”) shall be amended, effective as of the date of NPS’
  signature below, as follows: 

  •   In the second bullet, delete the
    “fifth, sixth, and seventh RESEARCH years” and insert therefor
    the words “fifth and sixth RESEARCH years, and at a level of one hundred
    seventy five thousand U.S. dollars (U.S. $175,000) per NPS FTE who is a lab
    personnel and at a level of one hundred fifty thousand U.S. dollars (U.S.
    $150,000) per NPS FTE who is a non-lab based consultant for the seventh RESEARCH
    year and at a level of two hundred twenty five thousand U.S. dollars (U.S.
    $225,000) per NPS FTE who is a non-lab based consultant for the eighth RESEARCH
    year, provided that it is understood that there will only be a total of two
    (2) NPS FTE’s during the seventh RESEARCH year and only a total of four
    (4) NPS FTE’s during the eighth RESEARCH year, and the levels outlined
    above will be applied on a pro-rata basis depending on the type of NPS FTE
    utilized.

  •   This Amendment Agreement shall be retroactively
    effective as of November 1, 2000.

•   All other terms
  and conditions of the Letter Agreement shall remain in full force and effect.

  
  
    Please indicate your acceptance of this January
      24, 2000 Amendment Agreement by signing and dating the duplicate copies
      of this letter below and returning one such fully executed copy to GSK.

    

  

	 	Very truly yours,
	 	SMITHKLINE BEECHAM CORPORATION
      

      (a GlaxoSmithKline Company)
	 	 	 
	 	By:	 /s/ Donald F. Parman
	 	 	     Donald
      F. Parman
	 	 Title: 	Secretary
	 	Date:	August 1, 2001

	AGREED TO AND ACCEPTED: 

      NPS PHARMACEUTICALS, INC.	 
	 	 	 
	By:	/s/ E. F. Nemith	 
	 	     E. F. Nemith	 
	Title:	CSO	 
	Date:	7 Aug 2001Prepared and filed by St Ives Burrups

Exhibit 10.9B

	 	

        March 15, 1993 
	NPS
      PHARMACEUTICALS, INC.

      CONFIDENTIAL

Janet E. Morris, V.M.D. 

  Technology Transfer Associate 

  Brigham Medical Center, Inc. 

  75 Francis Street

  Boston, MA 02115

RE:     Letter
  Agreement for Patent Agreement Dated February 19, 1993

Dear Ms. Morris:

  This letter will act to amend our Patent Agreement
    recently executed between NPS and the Hospital effective February 19, 1993.

  NPS and the Hospital have found that the executed
    Patent Agreement contained a typographical error in the paragraph which appears
    therein as paragraph 5. C. As executed, that paragraph reads as follows:

  C.     The license granted
    hereunder shall be fully paid up and no
    further royalties shall be payable when total royalties paid hereunder have
    reached $15,000,000.00

The parties hereby agree
  that it was the mutual intention of the parties that said paragraph 5. C. was
  to have read as follows, and the following language hereby is substituted for
  and completely replaces the earlier language. The agreed upon language of paragraph
  5. C. is to read as follows:

C.     In
  no calendar year will actual royalties payable to the Hospital exceed $1,000,000,
  provided that any earned royalties not paid in one calendar year due to this
  provision may be rolled over to any subsequent year for use toward this maximum
  yearly royalty. The license granted hereunder shall be fully paid up and no
  further royalties shall be payable when total royalties paid hereunder have
  reach $15,000,000.

  

  

  

  NPS PHARMACEUTICALS, INC. 420 CHIPETA WAY, SALT
  LAKE CITY, UT 84108 801-583-4939 FAX: 801-583-4961 

	 	 	NPS
      PHARMACEUTICALS, INC.

      CONFIDENTIAL

 Janet E. Morris, V.M.D. 

  Page Two 

  March 15, 1993 

 

        Except as
    amended hereby, the Patent Agreement remains in full force and effect. This
    amendment is deemed effective from the initial effective date of February
    19, 1993.

        To indicate
    your agreement herewith, please sign in the space provided and return to the
    undersigned. An additional signed copy is enclosed for your records.

	 	 Very truly yours,

        

        NPS PHARMACEUTICALS, INC.

       /s/ JAMES U. JENSEN

        James U. Jensen 

        Vice President, Corporate 

        Development and Legal Affairs

ACCEPTED AND AGREED TO AS 

  PROVIDED HEREIN 

 THE BRIGHAM AND WOMEN’S 

  HOSPITAL, INC. 

 By: /s/ [Illegible]

  

  Its: Vice President

 JUJ/sja 

 Enclosure 

 cc:      Hunter
  Jackson, Ph.D.Prepared and filed by St Ives Burrups

 Exhibit 10.9D

1999 Patent Agreement Amendment

  between

  THE BRIGHAM AND WOMEN’S HOSPITAL, INC. 

  and

  NPS PHARMACEUTICALS, INC.

  Effective February 18, 1999, The Brigham and
    Women's Hospital, Inc., a Massachusetts not-for-profit corporation having
    its principal offices at 75 Francis Street, Boston, Massachusetts 02115 (the
    “Hospital”), and NPS Pharmaceuticals, Inc., a Delaware corporation
    having its principal offices at 420 Chipeta Way, Salt Lake City, Utah 84108
    (the “Company”) agree as follows:

	1.	BACKGROUND

  The Hospital and the Company entered into a certain
    Patent Agreement effective February 19, 1993, amended by a letter agreement
    dated March 15, 1993, and by paragraph 5 of the Research Agreement Amendment
    effective December 10, 1993 and further amended by the 1996 Patent Agreement Amendment effective February 7, 1996 (collectively,
    the “Original Patent Agreement”).

  The Hospital and the Company now wish to amend
    said Original Patent Agreement pursuant to the terms of this 1999 Patent Agreement
    Amendment (the “1999 Patent Agreement Amendment”). This 1999 Patent Agreement
    Amendment shall become effective the date first above written.

	2.	AMENDMENTS.
      The Original Patent Agreement as in effect on
      the effective date hereof, is hereby amended by this 1999 Patent Agreement
      Amendment as follows:   
	 	 	 	 	 
	 	2.1	The term “Licensed
      Product(s)” contained in paragraphs 1.B, 4.A, 4.D, 5.A, 5.B, 6.A,
      6.C, 7.C, 7.D, 7.E, 13.A and 13.B of the Original Patent Agreement is hereby
      stricken and is replaced in all instances by the term “Royalty Bearing
      Products.”   
	 	 	 	 	 
	 	2.2	Paragraph 1.E. is
      hereby amended by inserting the following phrase “and/or in the Royalty
      Bearing Patents” immediately after the term “Licensed Patents”
      in the third line of such paragraph.   
	 	 	 	 	 
	 	2.3	The Original Patent
      Agreement is hereby amended to include the additional defined terms as follows:   
	 	 	 
	 	 	2.3.1	“Brown Funded
      Research Program” shall mean the research program as defined in the
      Complete Research Agreement (defined below) as said research program is
      amended and in effect from time to time under said Complete Research Agreement.
      Where appropriate, references to the “Brown-Hebert Funded Research
      Program” shall also include the “Brown Funded Research Program.”
	 	 	 	 	 
	 	 	2.3.2	“Complete Research
      Agreement” as used herein shall mean collectively that Research Agreement
      entered into by the Hospital and the Company effective February 19, 1993
      (the “Initial Research Agreement”) as amended by the   

1

	 	Research Agreement Amendment effective December
        10, 1993 (the “1993 Research Agreement Amendment”), the 1996 Research
        Agreement Amendment effective February 7, 1996 (the “1996 Research Agreement
        Amendment”) the 1997 Research Agreement Amendment effective March 1, 1997,
        and as further amended by the 1998 Research Agreement Amendment effective
        the date hereof (the “1998 Research Agreement Amendment”).

	 	 	 	 
	 	 	2.3.3	“Extended Performance
      Period” shall mean that period beginning on March 1, 1996 and ending on
      the earlier of (i) February 29, 2000, or (ii) such earlier date of termination
      of the Extended Performance Period as shall be effected by the Company under
      the terms of the Complete Research Agreement.
	 	 	 	 
	 	 	2.3.4	“Principal Investigator(s)”
      shall mean Dr. Edward M. Brown.
	 	 	 	 
	 	 	2.3.5	“Royalty Bearing
      Patents” shall mean the following patent applications: U.S. Serial No.:
      08/546,998, U.S. Serial No.: 08/846,721, Japan Serial Nos.: 178315/96, 107778/97,
      and 350393/96, any patents granted on such U.S. and Japanese applications,
      and any continuations, continuations-in-part, divisionals, reissues or re-examinations
      and any corresponding foreign filings thereof.
	 	 	 	 
	 	 	2.3.6	“Royalty Bearing
      Products” shall mean (i) Licensed Products, and (ii) any product or process,
      the manufacture, use (including discovery testing and development), sale,
      or import of which falls within the scope of Valid Claims of Royalty Bearing
      Patents.
	 	 	 	 
	 	2.4	Subparagraphs 5.G.
      and 5.H. of the Original Patent Agreement (taking into account the amendment
      thereof by the 1996 Patent Agreement Amendment) dealing with royalties are
      hereby amended in their entirety as follows:
	 	 	 	 
	 	 	G.	Upon occurrence of
      the following event(s), the Company shall incur (and within ninety (90)
      days thereafter shall pay) the following Prepaid Royalty(ies):
	 	 	 	 	 
	 	 	Event	Prepaid Royalty(ies)
	 	 	 	The Hospital has “delivered”
      to the Company a Secondary Functional Assay, previously identified as part
      of the Brown-Hebert Funded Research Program and/or the Brown Funded Research
      Program	$50,000.00
	 	 	 	 	 
	 	 	 	The parties acknowledge
      and agree that for purposes hereof, the event of “delivery of such
      a Secondary Functional Assay” will be deemed to occur on the date
      when the Secondary Functional Assay is first described in detail in writing
      to the Company provided however, that said delivery is followed within ninety
      (90) days by (i) the Company’s verification of the information presented
      to the Company, and (ii) the Company’s establishment of the “Secondary
      Functional 

	 

2

	 	 	 	Assay Utility” of said Secondary
      Functional Assay as described in paragraphs 3.i and 3.j hereof.
	 	 	 	 
	 	 	H.	Notwithstanding any other provision
      hereof for the payment of Prepaid Royalties, the Company shall have no obligation
      (i) to pay the specified Prepaid Royalty under 5.f. or 5.g. if on the date
      of “delivery” the Extended Performance Period has then expired
      or otherwise been terminated, or (ii) to pay in the aggregate, more than
      $500,000 of Prepaid Royalties from all payments combined. The Company shall
      receive credit against earned royalty payment obligations otherwise due
      in a given year, for all Prepaid Royalty(ies) made under the Original Patent
      Agreement as amended by this 1999 Patent Agreement Amendment, provided however,
      that the application of such credit shall not reduce earned royalties payable
      in a particular year below fifty percent (50%) of the earned royalties otherwise
      payable for such year. Uncredited Prepaid Royalty(ies) shall be rolled over
      in like manner to the next succeeding earned royalty year. Credits shall
      apply against any earned royalty obligation of the Company under the Original
      Patent Agreement as amended hereby.
	 	 	 	 

	 	 	 
	3.	TERMS	 

  Except as amended by this 1999 Patent Agreement Amendment,
    the Original Patent Agreement remains in full force and effect pursuant to
    the terms thereof.

  

  EXECUTED by the respective duly authorized officers or agents
    of the Hospital and the Company to be effective as of the date and year first
    above written.

	NPS PHARMACEUTICALS,
      INC.	THE BRIGHAM AND
      WOMEN’S HOSPITAL INC.
	 	 	 	 
	By:	 /s/ •	By: 	/s/ BRIAN N. HICKS
	 	 	 	      Brian
      N. Hicks
	Its: 	Vice President Corp. Developments
      Legal Affairs	Its:.	 Director Corporate Sponsored
      Reasearch and Licensing
	Date: 	March 1, 1999	Date:	 March 22, 1999

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}]]